Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 9Tumor-Agnostic 3Gastrointestinal 2Thoracic 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Pancreatic Neoplasms 1Gastrointestinal Stromal Tumors 1

Interventions

Fluorouracil 286Oxaliplatin 274Gemcitabine 222Capecitabine 221Leucovorin 219Bevacizumab 200Irinotecan 170pembrolizumab 141Cisplatin 132Cetuximab 111Radiotherapy 109Sorafenib 75Nivolumab 75130-nm albumin-bound paclitaxel 64Paclitaxel 63Albumin-Bound Paclitaxel 63Docetaxel 61Erlotinib Hydrochloride 57Panitumumab 56Radiosurgery 47Folfox protocol 46regorafenib 45Sunitinib 40Radiation 39Magnetic Resonance Spectroscopy 38durvalumab 33Surgical Procedures, Operative 33Ramucirumab 33Trastuzumab 32Cyclophosphamide 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × olaratumab × Gastrointestinal × Clear all
NCT03086369 2022-06-28

A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer

Eli Lilly and Company

Phase 1/2 Completed
184 enrolled 22 charts
Gastrointestinal

Pancreatic Neoplasms

NCT01316263 2017-03-09

A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors

Eli Lilly and Company

Phase 2 Terminated
21 enrolled 24 charts
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡